Apogee Therapeutics CEO Michael Henderson Sells 20,000 Shares Under 10b5-1 Plan

Michael Henderson, CEO and Director of Apogee Therapeutics, Inc., sold 20,000 shares of common stock on June 10, 2026, through a pre-arranged Rule 10b5-1 trading plan. The transactions were executed in six separate sales at weighted average prices ranging from $82.21 to $86.89 per share, with total proceeds of approximately $1.7 million. Following these sales, Henderson's ownership decreased from 1,111,757 shares to 1,095,987 shares. The sales were conducted pursuant to a trading plan adopted on August 13, 2025, and all transactions were reported as direct ownership. This Form 4 filing represents routine insider trading activity under a pre-established plan rather than discretionary market timing.